Taken together, these results revealed a signaling pathway from skeletal muscles to the liver via the IRF4-FSTL1-DIP2A/CD14 pathway in the pathogenesis of NASH. Here, FSTL1 is linked to metabolic dysfunction-associated steatohepatitis.